|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||300.00 - 300.00|
|52 Week Range||235.74 - 301.60|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||24.43|
|Forward Dividend & Yield||8.63 (2.89%)|
|1y Target Est||N/A|
Dollar trading volume on OTC Markets topped $29 billion in October, approximately a 4.5% increase from September. For the month, total dollar volume on the OTCQX Market, the top tier of OTC Markets, was ...
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million.
Bayer Shows Strength Across Portfolio as Litigation Concerns Continue Bayer BAYRY reported third-quarter results largely in line with our projections. We continue to view the company as undervalued, with the market attributing too much concern to the ongoing glyphosate litigation.
Investing in pharmaceutical companies is never easy. But with Biogen (NASDAQ:BIIB), that sentiment is multiplied a hundred fold. A nasty part of this business is that everything rides on key, flagship drugs. With science being the ultimate skeptic, passing clinical muster is an absolute. And Biogen stock demonstrated how critical this concept is within this year.Source: Shutterstock At the start of 2019, BIIB stock got off to a quick lead. Although shares have been frustratingly choppy over the trailing five years, Biogen did have one ace up its sleeve: aducanumab. A groundbreaking drug designed to slow cognitive decline in some Alzheimer's disease patients, Biogen began conducting clinical trails a few years back.However, in March of this year, the pharmaceutical halted two late-stage trails for aducanumab. Unfortunately for both Biogen engineers and hopeful patients, an independent audit revealed that the drug was likely ineffective. Upon the news, Biogen stock collapsed more than 29%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd between that point and Oct. 21, BIIB stock really didn't move much. Everything hinged on aducanumab, which represented - excuse the expression - a pharmaceutical cash cow. * 7 Stocks to Buy in November However, that same failed drug was responsible for a massive upswing in Biogen stock a day later on Oct. 22. Essentially, the Food and Drug Administration gave the green light for the underlying company to reapply for aducanumab's approval.Going on the media circuit, Biogen CEO Michel Vounatsos expressed confidence that this time, aducanumab will receive FDA approval. But how likely is such an event, and how should investors approach BIIB stock?We'll take a look at the good, the bad, and the ugly. The Good News for Biogen StockAccording to Vounatsos, the key reason why aducanumab failed was due to a small sample size. Additionally, the first round of clinical trials did not feature dosage diversity. Basically, Biogen did not give patients a strong enough dosage.However, a new analysis on a much larger data set with the higher dosages revealed a stronger mitigation of Alzheimer's disease symptoms. This encouraged Biogen to discuss the fresh findings with the FDA, leading to the green light to reapply.Of course, this does not guarantee that aducanumab will ultimately receive FDA approval. There's a big difference between applying for an Ivy League school and getting into one. And while Vounatsos has emphasized his confidence, I would expect that from any CEO.Still, it gives aducanumab a chance. For now, that's all investors need, having pushed BIIB stock roughly to where it was a year ago.But there's also a human component to aducanumab. The Alzheimer's Association estimates that 5.8 million Americans suffer from the disease. Further, it's the sixth leading cause of death in the U.S. If aducanumab works as advertised this time around, it would represent a medical breakthrough.Plus, with so many people suffering from Alzheimer's, Biogen stock will be worth its weight in gold. The Bad News for BIIBAlthough the enthusiasm is palpable for Biogen stock, investors should take a breather before acting on it. As with any equity, you don't want to jump in after a big move without some serious thought.While the reasons forwarded for why the first trial of aducanumab failed makes sense, it doesn't necessarily mean that this latest analysis implies a tangible success for the drug. And investors, medical researchers and patients have reasons to be skeptical.Indeed, I would guess that any intellectually honest medical doctor would advise his or her patient to keep grounded. First, no one outside of Biogen has seen the details of this larger data set analysis. Thus, without peer review, it's hard to generate much excitement.As Dr. Michael Weiner, Alzheimer's researcher at the University of California, San Francisco, told the New York Times, aducanumab could spark "the dawn of a new era." However, Weiner noted that this is not a cure, but rather, "It is a slowing of decline. The practical impact on patients remains to be seen."Not only that, research for Alzheimer's and other dementia-related diseases is littered with failure. Roche (OTCMKTS:RHHBY), Eli Lilly (NYSE:LLY), AstraZeneca (NYSE:AZN), Pfizer (NYSE:PFE) and Merck (NYSE:MRK) have all abandoned this market.You can look at it two ways for BIIB stock: it's a massive opportunity if the company wins, but that probability is very, very low. And Finally, the UglyThus, comes the million-dollar question: how should investors approach Biogen stock?Here's the ugly truth: I have no idea. And I suspect that most analysts feel the same.Without the peer-reviewed analysis of Biogen's new study, investors are operating in the dark. Therefore, if I had to make a guess, I would rely on what we do know. And that is Alzheimer's treatments have a bad track record.Even Biogen's initial clinical trial failed when held to an independent audit. Therefore, BIIB has the credibility hurdle. Given that we won't know the details for some time, gambling on Biogen stock right now seems risky.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post The Good, Bad, and Ugly for Biogen Stock appeared first on InvestorPlace.
A new study finds evidence that Jane Jacobs was right about the dynamic and innovative qualities spurred by living in dense, urban neighborhoods.
Walmart reported its Q3 earnings, posting revenues of nearly $128 billion, and adjusted earnings that beat estimates. Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Julia La Roche discuss the retailer’s big win.
Dirk Van de Put, CEO of Mondelēz International (NASDAQ: MDLZ), talks to Yahoo Finance's Julia La Roche about the company's global strategy and reveals the findings of a recent study about snacking behavior.
Uber is facing a PR disaster after CEO Dara Khosrowshahi told Axios that the killing of American journalist Jamal Khashoggi was "a serious mistake" and then compared it to Uber's own "mistakes" with self-driving experiments. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Facebook announced that Instagram could begin hiding "likes" on some U.S. accounts as early as this week. Users will still be able to see likes on their own posts, but those counts will not be visible to others viewing your post. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Amazon third-party sellers are suspended from making sales due to an email glitch. Yahoo Finance’s Dan Roberts, Heidi Chung and Julia La Roche discuss on YFi-AM.
Zillow’s shares soar after the online real estate company beat revenue estimates for the third-quarter. Yahoo Finance’s Dan Roberts, Julia La Roche and Heidi Chung discuss on YFi AM.
Yahoo Finance's Dan Roberts, Julia La Roche, and Heidi Chung discuss the long-awaited streaming platform, Disney+, and how it will disrupt the streaming wars.
Tinder Co-founder Sean Rad joins Yahoo Finance's Zack Guzman, Kristin Myers and Julia La Roche to discuss the latest developments on the $2B lawsuit against IAC. Rad also discusses the outlook on the dating app industry and chats about his new nonprofit.
A group of former Tinder executives sued IAC for $2 billion after ex-employees accused IAC for undervaluing the dating app and allegedly being cheated out of stock options. Tinder's Co-Founder Sean Rad joins Yahoo Finance's Zack Guzman and Julia La Roche to discuss the latest developments on the lawsuit, on YFi PM.
Microsoft Japan tested out a 4-day workweek for all of August as part of its Work-Life Choice challenge. Employees were still paid for their Fridays off, and the results showed that employee productivity rose by 40%, the number of papers printed was reduced by 58%, and electricity consumption was reduced by 23%. Japan has some of the longest working hours in the world, with 1 in 4 companies expecting their employees to work 80 hours overtime a month, according to a government study.
Goldman Sachs is making changes to be more family-friendly for its employees. In an internal memo obtained exclusively by Yahoo Finance, Goldman says it will offer all new parents 20 weeks paid leave, regardless of caregiver status. The bank will also add other benefits to help all groups on their path to parenthood.
Berkshire Hathaway has reported a record high cash pile to end the third quarter. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss on YFi-Am.
The National Highway Traffic Safety Administration is looking into potential defects in Tesla's battery packs after "an alarming number of car fires that have occurred worldwide," according to a letter the regulator sent to the electric carmaker. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss on YFi AM.
The utility company is under pressure after California Governor Gavin Newsom threatened to take over PG&E, unless the company exits bankruptcy and improves its operations. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss on YFi AM.
Under Armour shares were overshadowed by investigations for accounting practices. Yahoo Finance’s Brian Sozzi, Alexis Christoforous and Julia La Roche discuss on The First Trade.
Starbucks out with its fourth quarter and fiscal year 2019 results. Yahoo Finance's Julia La Roche reports to Jen Rodgers, Myles Udland, and Dan Roberts.